Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.
about
Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantationA therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantationComparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantationA therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantationComparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantationAlternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantationDifferent doses of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantationTreatment for disseminated intravascular coagulation in patients with acute and chronic leukemiaTreatment for disseminated intravascular coagulation in patients with acute and chronic leukemiaPathophysiology, clinical features and radiological findings of differentiation syndrome/all-trans-retinoic acid syndromeWhy has demand for platelet components increased? A reviewAcute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patientsAlternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation.The regulatory role of cell mechanics for migration of differentiating myeloid cells.Thromboembolic and bleeding complications in acute leukemia.Curing all patients with acute promyelocytic leukemia: are we there yet?Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapyTreatment advances have not improved the early death rate in acute promyelocytic leukemia.SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3.A Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adultsDoes microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA GroupInfections in pediatric acute promyelocytic leukemia: from the Canadian infections in acute myeloid leukemia research group.Clinical characteristics, outcome and early induction deaths in patients with acute promyelocytic leukaemia: a five-year experience at a tertiary care centreExpression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell countsPrognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy.Treatment of Acute Promyelocytic Leukemia with AIDA Based Regimen. Update of a Tunisian Single Center StudyDifferentiation syndrome in promyelocytic leukemia: clinical presentation, pathogenesis and treatment.Epidemiology and treatment of acute promyelocytic leukemia in latin americaAcute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid eraThe differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literatureNewly diagnosed acute promyelocytic leukemiaAddition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic LeukemiaMutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic TrioxideAbsolute quantification of the pretreatment PML-RARA transcript defines the relapse risk in acute promyelocytic leukemiaAnalysis of factors affecting hemorrhagic diathesis and overall survival in patients with acute promyelocytic leukemiaOutcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.Treatment of acute promyelocytic leukemia for older patients.New strategies in acute promyelocytic leukemia: moving to an entirely oral, chemotherapy-free upfront management approach.Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid
P2860
Q24186359-3E622D91-34A7-4B25-8B4E-96A9F97327C7Q24186913-4A19C1D4-E2D5-4236-9D08-EA9C7157CAA7Q24187751-A7190DA9-8D03-4BFE-97CB-884DE5F1DC29Q24198288-33DA2E79-7EEE-4350-B8FF-67026E941F82Q24198774-6681ADC0-3BE6-4201-9214-C95D55272B32Q24198795-BF8FF2AF-81C9-4FAD-8171-32B24A49EFF5Q24198832-5C8B077F-7465-4AD0-96B4-D0A8E5283A4CQ24235126-05055AFD-94A0-4371-9B3A-A84EA0F7CC6FQ24236433-368D8E82-AD12-4851-A10D-5EA3506F0F2EQ27012691-20625552-EAC3-4584-ACBF-D068AAE515D9Q28249969-F03E84B2-2749-423D-8FAA-5FB3D5A6EADEQ28286577-178D9023-05EA-4FE5-951A-6E19FB259935Q30248355-5E2F7AB5-C0D6-4303-ADD0-BEC94B131A3EQ30490345-C2AB1462-FEE4-4221-A763-545D4F864FECQ33392897-4A5710CE-A7C5-4153-8F7B-512E0FA6553CQ33613426-861DF18C-D4F5-4980-88D1-C7AA2733F70BQ33707423-30717877-DD7F-489F-981C-5FE14815B2A2Q33781722-4D8A3E64-3AD5-4D80-BB47-AEACDB538179Q34223654-38009128-78B3-4130-9821-669B56516A8BQ34226368-406B879F-E84E-46AA-891E-D8CBFFCEEB36Q34305899-31508473-81E3-4931-81BA-D1B92FA3E752Q34541742-B5C2A354-D316-4B8C-A955-D03A8443553CQ34756538-76B677B7-7603-4EC0-BD49-65BCEDBB9924Q34953881-8ED002C9-8D6F-4B53-8886-9E100F56BDC2Q35051695-819A70FA-A7F2-4665-8A03-3E3949B17E8BQ35265901-01B5D899-601E-4823-A3B3-A633A5ED8A96Q35540812-FCD0D7C6-C17E-4202-96E7-33C33F1C889BQ35560264-36E46986-8C2D-47CD-8622-90392621CC2FQ35560268-4FE35BF1-A602-4AAD-99E0-648BC118E4E6Q35640734-B3E6EEB1-1E76-4F97-A6FB-8E6BF99908A2Q35640755-27007EF5-CC2B-44B5-8832-3CE62C6E4219Q35640773-0916D26C-47A7-4587-9D23-9D58A4A394D1Q35904994-9658D98A-B7A2-4E81-A93A-64DA1DB3513CQ35949253-5620E453-7D55-4FFE-98ED-3F1FFB21DBEEQ35955272-C264BE17-DB78-4B15-AA58-0FC5D592088FQ36272117-5A9CD9B7-5695-42B6-A923-25AA13E5BB79Q36508333-E2BFE372-6842-4DB6-9802-B278307A8795Q36672084-16184321-225E-4D18-9E51-F91B1A97AED6Q36941941-7C8CE141-9BE0-4189-801C-FDFF1B558DFCQ37216174-52E53A32-98B9-4801-9252-3E66B9E127B2
P2860
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Causes and prognostic factors ...... retinoic acid and idarubicin.
@en
type
label
Causes and prognostic factors ...... retinoic acid and idarubicin.
@en
prefLabel
Causes and prognostic factors ...... retinoic acid and idarubicin.
@en
P2093
P50
P1433
P1476
Causes and prognostic factors ...... s retinoic acid and idarubicin
@en
P2093
Angel León
Bob Lowenberg
Chelo Rayón
Concha Rivas
Edo Vellenga
Elena Amutio
Guillermo Debén
Gustavo Milone
Joaquín Díaz-Mediavilla
Jordi Esteve
P304
P356
10.1182/BLOOD-2007-07-100669
P407
P577
2008-01-14T00:00:00Z